Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $93,744.09 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 4,117 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $22.77, for a total value of $93,744.09. Following the transaction, the insider directly owned 77,484 shares in the company, valued at $1,764,310.68. This represents a 5.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Down 3.4%

Shares of KMTS opened at $25.06 on Thursday. Kestra Medical Technologies, Ltd. has a fifty-two week low of $14.10 and a fifty-two week high of $30.00. The business has a 50-day moving average of $22.78 and a 200 day moving average of $22.52. The firm has a market cap of $1.47 billion, a P/E ratio of -10.36 and a beta of 0.58. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. As a group, research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Analyst Upgrades and Downgrades

KMTS has been the subject of several analyst reports. Oppenheimer began coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. The Goldman Sachs Group dropped their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a report on Wednesday, July 15th. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, BTIG Research increased their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $27.83.

Institutional Trading of Kestra Medical Technologies

Several institutional investors and hedge funds have recently bought and sold shares of KMTS. Farther Finance Advisors LLC bought a new position in Kestra Medical Technologies in the 4th quarter valued at $31,000. Russell Investments Group Ltd. increased its holdings in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the period. Daiwa Securities Group Inc. purchased a new stake in shares of Kestra Medical Technologies in the fourth quarter worth $72,000. BNP Paribas Financial Markets boosted its stake in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the period. Finally, Brown Brothers Harriman & Co. grew its position in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.